PMID- 31115490
OWN - NLM
STAT- MEDLINE
DCOM- 20191127
LR  - 20200225
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 44
IP  - 1
DP  - 2019 Jul
TI  - EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis 
      by downregulating EGFR.
PG  - 79-88
LID - 10.3892/ijmm.2019.4190 [doi]
AB  - In hepatolithiasis, chronic proliferative cholangitis (CPC), an active and 
      longstanding inflammation of stone‑containing bile ducts with enhanced 
      mucin‑producing activity, not only affects the progression of the disease, it can 
      also induce biliary carcinogenesis. The present study aimed to examine the effect 
      of the epidermal growth factor receptor (EGFR) monoclonal antibody panitumumab 
      (Pani) on CPC. Following the establishment of CPC rat models, periodic acid 
      Schiff staining was used to observe the positive rate of EGFR expression. The 
      expression levels of EGFR, mucin 5AC (MUC5AC), Ki‑67, type I collagen and 
      mammalian target of rapamycin (mTOR), and the activity of beta‑glucuronidase (beta‑G), 
      were measured. The rats treated with Pani demonstrated a significantly lower 
      degree of hyperproliferation of the epithelium and submucosal glands of the bile 
      duct and collagen fibers of the bile duct wall, a significantly decreased 
      positive rate of EGFR, reduced phosphorylation of mTOR, decreased expression of 
      EGFR, MUC5AC, Ki‑67 and type I collagen, and reduced beta‑G activity. The 
      therapeutic effects in rats treated with 4 and 6 mg/kg of Pani were more marked 
      than those in rats treated with 2 mg/kg of Pani. Collectively, the data obtained 
      in the present study suggest that the EGFR monoclonal antibody Pani can 
      effectively inhibit the excessive proliferation and stone‑forming potential of 
      bile duct mucosa in CPC with a receptor saturation effect. Therefore, Pani offers 
      promise as a treatment for the prevention and control of intrahepatic 
      choledocholithiasis caused by CPC.
FAU - Liu, San-Hu
AU  - Liu SH
AD  - Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical 
      University, Guangzhou, Guangdong 510515, P.R. China.
FAU - Chen, Xue-Fang
AU  - Chen XF
AD  - Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical 
      University, Guangzhou, Guangdong 510515, P.R. China.
FAU - Xie, Zhi-Bin
AU  - Xie ZB
AD  - Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical 
      University, Guangzhou, Guangdong 510515, P.R. China.
FAU - Zhou, Jie
AU  - Zhou J
AD  - Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical 
      University, Guangzhou, Guangdong 510515, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190509
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 6A901E312A (Panitumumab)
RN  - EC 2.7.10.1 (Egfr protein, rat)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Bile Ducts/*metabolism/pathology
MH  - Cell Proliferation/*drug effects
MH  - Cholangitis/*drug therapy/metabolism/pathology
MH  - Chronic Disease
MH  - Down-Regulation/*drug effects
MH  - ErbB Receptors/*biosynthesis
MH  - Male
MH  - Panitumumab/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC6559293
EDAT- 2019/05/23 06:00
MHDA- 2019/11/28 06:00
PMCR- 2019/05/09
CRDT- 2019/05/23 06:00
PHST- 2018/07/18 00:00 [received]
PHST- 2019/04/16 00:00 [accepted]
PHST- 2019/05/23 06:00 [pubmed]
PHST- 2019/11/28 06:00 [medline]
PHST- 2019/05/23 06:00 [entrez]
PHST- 2019/05/09 00:00 [pmc-release]
AID - ijmm-44-01-0079 [pii]
AID - 10.3892/ijmm.2019.4190 [doi]
PST - ppublish
SO  - Int J Mol Med. 2019 Jul;44(1):79-88. doi: 10.3892/ijmm.2019.4190. Epub 2019 May 
      9.